Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study. Liu J, Zhang J, Li H, Song G, et al. BMC Cancer 2025;25:9.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Liu J, Zhang J, Li H, Song G, et al. Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study. BMC Cancer 2025;25:9.
PMID: 39754078